William Rice, CEO and Greg Chow, CFO of Aptose Biosciences Molecule Expected to Return to Clinic
Released Wednesday, 30th May 2018
Good episode? Give it some love!
William Rice, CEO and Greg Chow, CFO of Aptose Biosciences Molecule Expected to Return to Clinic
William Rice, CEO and Greg Chow, CFO of Aptose Biosciences Molecule Expected to Return to Clinic
Wednesday, 30th May 2018
Good episode? Give it some love!
Rate Episode
Rate
From The Podcast
Aptose Biosciences Inc. (TSX: APS)
Podcast with news and updates from Aptose Biosciences (NASDAQ: APTO, TSX: APS), a science-driven biotechnology company advancing first-in-class agents to treat life-threatening cancers, such as acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS) and other hematologic malignancies. Based on insights into the genetic and epigenetic profiles of certain cancers and patient populations, Aptose is building a pipeline of novel oncology therapies directed at dysregulated processes and signaling pathways.Join Podchaser to...
- Rate podcasts and episodes
- Follow podcasts and creators
- Create podcast and episode lists
- & much more
Episode Tags
Do you host or manage this podcast?
Claim and edit this page to your liking.
,Claim and edit this page to your liking.
Unlock more with Podchaser Pro
- Audience Insights
- Contact Information
- Demographics
- Charts
- Sponsor History
- and More!
- Account
- Register
- Log In
- Find Friends
- Resources
- Help Center
- Blog
- API
Podchaser is the ultimate destination for podcast data, search, and discovery. Learn More
- © 2024 Podchaser, Inc.
- Privacy Policy
- Terms of Service
- Contact Us